FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Failla Anton Giorgio 2. Date of Event Requiring Statement (Month/Day/Year) 07/28/2009 3. Issuer Name and Ticker or Trading Symbol CORNERSTONE THERAPEUTICS INC [CRTX] (Last) (First) (Middle) C/O CHIESI FARMACEUTICI SPA, VIA PALERMO 26/A 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) PARMA, L6 43122 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Failla Anton Giorgio C/O CHIESI FARMACEUTICI SPA VIA PALERMO 26/A PARMA, L6 43122	  X	Â	Â	Â

Signatures

/s/ Anton Giorgio Failla		08/06/2009
**Signature of Reporting Person		Date

Explanation of Responses:

No securities are beneficially owned
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  Remarks: On July 28, 2009, Chiesi Farmaceutici SpA, a corporation organized under the laws of Italy, closed on its transaction to purchase from Cornerstone Therapeutics Inc. (the "Company") 11,902,741 newly issued shares of common stock, par value $0.001 per share, of the Company ("Common Stock"), subject to future adjustment, and an aggregate of 1,600,000 shares of Common Stock from entities controlled by Craig A. Collard, the President and Chief Executive Officer of the Company, and Steven M. Lutz, the Executive Vice President, Manufacturing and Trade of the Company.  In connection with the closing of this transaction, effective July 28, 2009, Mr. Failla was elected as a director of the newly constituted Board of Directors of the Company.  Mr. Failla does not currently own any shares of Common Stock or options to purchase shares of Common Stock of the Company No securities are beneficially owned. Exhibit List Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.